Skip to main content

Table 4 Inter-patient and Intra-patient variability of C min and C max for each antiretroviral agent

From: Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study

    Cmin Cmax
Antiretroviral agent   n Mean (SD) Inter-patient CV Intra-patient CV median (IQR) Mean (SD) Inter-patient CV Intra-patient CV median (IQR)
Atazanavir 400 QD 9 250.4 (195.4) 78.0% 57.4 (40.5-86.7) 2000.4 (1145.5) 57.3% 61.9 (44.2-66.0)
Atazanavir (boosted with ritonavir) 300 QD 18 1065.6 (699.2) 65.6% 26.3 (15.6-56.1) 3525.3 (1459.1) 41.4% 32.7 (17.2-54.5)
Lopinavir (boosted with ritonavir) 400 BID 16 6370.0 (2846.4) 44.7% 23.8 (12.8-75.8) 8991.3 (2953.3) 32.8% 14.0 (12.3-21.7)
Lopinavir (boosted with ritonavir) 800 QD 4 5356.2 (3882.3) 72.5% 63.4 (35.2- 115) 11151.3 (4433.2) 39.8% 15.6 ( 7.4-28.4)
Efavirenz 600 QD 16 2196.9 (1209.2) 55.0% 17.7 (10.5-25.1) 3929.4 (2060.6) 52.4% 15.5 (12.8-27.9)
Nevirapine 200 BID 11 5693.6 (2586.8) 45.4% 13.9 (10.2-27.8) 6490.9 (2454.9) 37.8% 10.7 ( 7.8-19.6)
Nevirapine 400 QD 8 5027.9 (2867.2) 57.0% 21.3 (12.1-44.9) 6924.4 (2761.1) 39.9% 22.8 ( 8.3-53.8)
  1. SD, Standard deviation; CV, Coefficient of Variation; IQR, Interquartile Range.